Pre-made Solitomab benchmark antibody ( Bispecific scFv, anti-EPCAM;CD3E therapeutic antibody, Anti-Ber-Ep4/BerEp4/DIAR5/EGP-2/EGP314/EGP40/ESA/HNPCC8/KS1/4/KSA/M4S1/MIC18/MK-1/MOC-31/TACSTD1/TROP1;T3E/TCRE/IMD18 Antibody) for drug discovery and mechanism of action (MOA) research

Cat No.: GMP-Bios-ab-528

Pre-Made Solitomab biosimilar, Bispecific scFv, Anti-EPCAM;CD3E Antibody: Anti-Ber-Ep4/BerEp4/DIAR5/EGP-2/EGP314/EGP40/ESA/HNPCC8/KS1/4/KSA/M4S1/MIC18/MK-1/MOC-31/TACSTD1/TROP1;T3E/TCRE/IMD18 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Solitomab (INN; development code MT110) is an artificial bispecific monoclonal antibody that is being investigated as an anti-cancer drug. It is a fusion protein consisting of two single-chain variable fragments (scFvs) of different antibodies on a single peptide chain of about 55 kilodaltons. One of the scFvs binds to T cells via the CD3 receptor, and the other to EpCAM as a tumor antigen against gastrointestinal, lung, and other cancers.

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-528-1mg 1mg Inquiry
GMP-Bios-ab-528-10mg 10mg Inquiry
GMP-Bios-ab-528-100mg 100mg Inquiry
GMP-Bios-ab-528-xmg ＞100mg Inquiry
Shipping Cost: 760.00
Total:

For more than 100mg, click here for inquiry. >>


Description

Products Name (INN Index) Pre-Made Solitomab biosimilar, Bispecific scFv, Anti-EPCAM;CD3E Antibody: Anti-Ber-Ep4/BerEp4/DIAR5/EGP-2/EGP314/EGP40/ESA/HNPCC8/KS1/4/KSA/M4S1/MIC18/MK-1/MOC-31/TACSTD1/TROP1;T3E/TCRE/IMD18 therapeutic antibody
INN Name Solitomab
TargetEPCAM;CD3E
FormatBispecific scFv
DerivationBispecific antibody
Species ReactivityHuman
CH1 Isotypena
VD LCKappa;Kappa
Highest_Clin_Trial (Jan '20)Phase-I
Est. StatusDiscontinued
100% SI StructureNone;None
99% SI StructureNone;None
95-98% SI StructureNone;None
Year Proposed2011
Year Recommended2012
CompaniesMicromet Inc;Amgen
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedSolid tumours
Development Techna

Case Study -- GeneMedi's GMP-Bios-ab-528 (Pre-Made Solitomab biosimilar) is validated to bind the Jurkat cells by Flow Cytometry (FACS Analysis)


GM R&D department tested the binding ability of GeneMedi's GMP-Bios-ab-528 (Pre-Made Solitomab biosimilar) to the Jurkat cells by Flow Cytometry. Below is the conclusion:

1.Good binding of GM-528 to Jurkat cells.

2.High concentration (10ug/ml) of GM-528 should be used for CD3 detection.

3.The CD3 antibody is derived from L2K. The affinity of L2K is about 35 times lower than OKT3. (Therapeutic Window of MuS110, a Single-Chain Antibody Construct Bispecific for Murine EpCAM and Murine CD3. Cancer Res. 2008)

Target products collection Target products collection

Figure 1. GeneMedi's GMP-Bios-ab-528 (Pre-Made Solitomab biosimilar) is validated to bind the Jurkat cells by Flow Cytometry (FACS Analysis).